Precision for Medicine Acquires ACT Oncology         

Posts by Jen Mahoney

Precision for Medicine to Acquire ACT Oncology

Precision for Medicine to Acquire ACT Oncology Establishes leading platform for Precision Medicine Oncology Research   Bethesda, Md. and Flemington, N.J., March 22, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively…

Read More

ACT Oncology Appoints New Chief Medical Officer

ACT Oncology (ACT), an oncology specialist Clinical Research Organization (CRO), is pleased to announce the appointment of Gerald Messerschmidt, M.D., FACP, as Chief Medical Officer (CMO).  Formerly a consultant for the company, Dr. Messerschmidt will provide medical and safety leadership in addition to lending his expertise to the development of Sponsors’ clinical development strategies.  Dr.…

Read More

EnGeneIC chooses ACT Oncology as CRO for planned Phase I/IIa study in US

EnGeneIC has appointed ACT Oncology as a CRO for its planned Phase I/IIa study with end-stage oncology patients using its EDV based technology, said joint managing director Himanshu Brahmbhatt.The company is also open to partnering it’s EDV Platform, he added. The Sydney, Australia based company has submitted an IND to the FDA for a truncated…

Read More

ACT Oncology President Named EY Entrepreneur Of The Year(R) New Jersey Finalist

ACT Oncology (ACT), an oncology-specialist, clinical research organization (CRO), announced today that Patricia Devitt-Risse, Pharm. D, President of the company, has been named a finalist for the Ernst & Young Entrepreneur Of The Year® 2015 Award for the state of New Jersey.  With selection administered by a panel of independent judges, this prestigious awards program…

Read More

ACT Oncology is very pleased to announce the promotion of Jeff Seroskie to Corporate Vice President.

Jeff has been instrumental in driving ACT Oncology’s growth and success since he joined the company in 2005. His strong leadership, strategic vision and overall performance have resulted in the award of several important programs.  Jeff’s outstanding operational expertise and steadfast commitment to providing exceptional service continue to drive ACT Oncology’s phenomenal repeat business rate.    …

Read More

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at precisionforoncology.com to see how we’re delivering the next generation of CRO services for oncology innovators.